Check all documented drug-to-drug interactions. Major, moderate, and minor interactions with descriptions.
A therapy excluded from this list does not necessarily mean no interaction exists between that therapy and Chenodal. Always confirm against the full prescribing information.
100 interactions
Acetylsalicylic acid
The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Chenodeoxycholic acid.
Level 1 evidence
Aluminium phosphate
Aluminium phosphate can cause a decrease in the absorption of Chenodeoxycholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
Level 1 evidence
Aluminum chloride
Aluminum chloride can cause a decrease in the absorption of Chenodeoxycholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
Level 1 evidence
Aluminum chlorohydrate
Aluminum chlorohydrate can cause a decrease in the absorption of Chenodeoxycholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
Level 1 evidence
Aluminum hydroxide
Aluminum hydroxide can cause a decrease in the absorption of Chenodeoxycholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
Level 1 evidence
Aluminum sulfate
Aluminum sulfate can cause a decrease in the absorption of Chenodeoxycholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
Level 1 evidence
Anagrelide
The risk or severity of adverse effects can be increased when Anagrelide is combined with Chenodeoxycholic acid.
Level 1 evidence
Apalutamide
The serum concentration of Chenodeoxycholic acid can be decreased when it is combined with Apalutamide.
Level 1 evidence
Aprepitant
The metabolism of Chenodeoxycholic acid can be decreased when combined with Aprepitant.
Level 2 evidence
Avanafil
The serum concentration of Avanafil can be increased when it is combined with Chenodeoxycholic acid.
Level 1 evidence
Berotralstat
The metabolism of Chenodeoxycholic acid can be decreased when combined with Berotralstat.
Level 2 evidence
Cangrelor
The risk or severity of adverse effects can be increased when Cangrelor is combined with Chenodeoxycholic acid.
Level 1 evidence
Enter your NPI to unlock 17 major interactions for Chenodal
Chenodal (Chenodiol) has 210 documented drug interactions. Always review the full list with a pharmacist before co-prescribing.
Chenodal (Chenodiol) has 46 major, 81 moderate, and 83 minor documented interactions.
A therapy excluded from this list does not necessarily mean no interaction exists between that therapy and Chenodal. Always confirm against the full prescribing information.